Lupin Launches Lotemax Generic

  Published 1 year ago

Lupin launches Loteprednol Etabonate Ophthalmic Suspension, a generic equivalent of Lotemax, targeting $55 million U.S. market.

  • Drug treats steroid-responsive eye inflammations and post-surgery swelling, matching Lotemax’s therapeutic efficacy.
  • Lotemax posted $55 million U.S. sales in May 2025, per IQVIA data; Lupin aims to capture share.
  • Mumbai-based Lupin distributes across 100+ markets, focusing on complex generics, APIs, and biotech solutions.

You might like these

BP's Financial Struggles & Future Reset

Karnataka's Fake News Bill Sparks Free Speech Fears

Kubota Combine Boosts Farmer Income

Markets Slip as RBI Holds Rates Steady

Senco Gold Surges 5% on Strong Q1 Sales

India Cement Consolidation Fuels Prices

Nifty, Sensex Edge Up on Trade Hopes

News that matters the most ⚡